


Volume 37 Number 2 March 2010




Photos courtesy of Health Sciences Information Media Service; Memorial University of Newfoundland"

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

Beyond whole brain


there's local control



Leksell Gamma Knife^{*} Perfexion^{**} treats multiple brain metastases in a single session, reducing the damage to healthy tissue that may limit future treatment options, and allowing for concomitant chemotherapy for optimum primary tumor control. Find out how Elekta is creating new possibilities for the most challenging cases at elekta.com/proof.



Leksell Gamma Knife* Perfexion



Single-session multiple mets



Human care makes the future possible



Volume 37 / Number 2 / March 2010

EDITORIALS

157 "It was the Best of Times, it was the Worst of Times"

G. Bryan Young

159 Neuropathology Training and Status in Canada *Samuel K. Ludwin*

AUTOBIOGRAPHY

160 More Personal Reflections on Life Part III. The Launch of a Journey Lasting 65 Years: Personal Observations Made From a Front-Row Seat at the Greatest Show on Earth

Henry J.M. Barnett

REVIEW ARTICLES

167 Current Evaluation and Management of Excessive Daytime Sleepiness

M.I. Boulos, B.J. Murray

177 MicroRNA Signatures in Neurological Disorders Gowhar Shafi, Nishat Aliya, Anjana Munshi

ORIGINAL ARTICLES

186 Prevalence of Mental Disorders in a Canadian Household Population with Dementia

Scott B. Patten, Alice Nabalamba

195 Duchenne Muscular Dystrophy: Canadian Paediatric Neuromuscular Physicians Survey

Hugh J. McMillan, Craig Campbell, Jean K. Mah, on behalf of the Canadian Paediatric Neuromuscular Group

206 Neuropathology in Canada: Overview of Development and Current Status

Marc R. Del Bigio, Edward S. Johnson

213 Neuronal Intranuclear Inclusion Disease Presenting as Juvenile Parkinsonism

Katie M. Wiltshire, Christopher Dunham, Stuart Reid, Roland N. Auer, Oksana Suchowersky

219 Non Ruptured MCA Aneurysms Presenting with Insular Related Symptoms

Ramez Malak, Dank Khoa Nguyen, Michel W. Bojanowski

223 Quercetin Administration After Spinal Cord Trauma Changes S-100β Levels

E. Schültke, R.W. Griebel, B.H.J. Juurlink

229 Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration

Hai-Yan Zhou, Yu-Yan Tan, Zhi-Quan Wang, Gang Wang, Guo-Qiang Lu, Sheng-Di Chen

235 Utility of Transcranial Doppler in Idiopathic Intracranial Hypertension

Gary Hunter, Chris Voll, Michele Rajput

240 Intra-Arterial vs Intra-Venous Thrombolysis for Anterior Cerebral Occlusion

Bin Zhang, Xiaojiang Sun, Minghua Li, Feng Wang, Dan Xu, Hao Duan, Chun Fang

245 Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service

Janice C. Fan, Tania M. Mysak, Thomas J. Jeerakathil, Glen J. Pearson

252 Risk Factors of Stroke in Pakistan: A Dedicated Stroke Clinic Experience

Fawad Taj, Rehan Zahid, Umm-e-Rubab Syeda, Muhammed Murtaza, Shahzad Ahmed, Ayeesha Kamran Kamal

258 Risk of Multiple Sclerosis after Idiopathic Optic Neuritis in a Pakistani Population

Syed Faraz Kazim, Muhammad Islam, Mustafa Khan, Bilal Hameed, Saad Shafqat

264 Selection Bias Introduced by Neuropsychological Assessments

Robert Olson, Maureen Parkinson, Michael McKenzie

NEUROIMAGING HIGHLIGHT

- 269 Vertebral Hemangioma Causing Spinal Cord Compression Eduardo de Pablo-Fernández, Cristina Dominguez-González
- 271 Congenital Ventral Thoracic Spinal Cord Herniation Aria Fallah, Michael G. Fehlings



Volume 37 / Number 2 / March 2010

BRIEF COMMUNICATIONS (formerly Case Reports)

273 Posterior Fossa Arachnoid Cyst Associated with Chiari I and Syringomyelia

Scott A. Marin, Christopher R. Skinner, Vasco F. Da Silva

276 Thoracic Myelopathy from Coincident Fluorosis and Epidural Lipomatosis

Lorraine V. Kalia, Liesly Lee, Suneil K. Kalia, Farhad Pirouzmand, Mark J. Rapoport, Richard I. Aviv, Dan Mozeg, Sean P. Symons

279 Primary Orbital Hemangiopericytoma: An Unusual Cause of Unilateral Proptosis

Rim Limaiem, Faten Limaiem, Nadia Kourda, Issam Zairi, Afif Chaabouni, Leila El Matri

283 Ruptured Aneurysm Arising from the Anterior Choroidal Artery's Cisternal Segment

Nancy McLaughlin, Michel W. Bojanowski

286 Subarachnoid Hemorrhage in Perivascular Spaces Mimicking Brainstem Hematoma

Manuel Ribeiro, Peter Howard, Robert A. Willinsky, Karel ter Brugge, Leodante da Costa

289 Long-Term Survival of a Patient with Glioblastoma

Adrian Sacher, Robert Wollmann, Urmi Kalokhe, David Munoz, Marie-Christine Guiot, R. Loch Macdonald

293 Conversion Disorder after Surgery in a Brain Tumour Patient *Kathleen Joy Khu, Sherese Ali, Mark Bernstein*

- 296 Thank you to Reviewers
- 297 Books Received/Books Reviewed
- 300 Calendar of Events
- A-18 Board of Directors/Committee Chairs
- A-3 CNSF 2010 Congress Program
- IBC CNSF Sponsors
- A-9 Information for Authors
- A-10 Information for Authors
- A-11 Job Postings
- A-17 Advertisers Index
- A-17 Classified Ads
- A-19 Annual Congress Registration and Hotel Details

REVIEWERS

The Editor-in-Chief, Associate Editors, and Journal Staff would like to acknowledge the generous contributions of the many reviewers for the 2009 Journal. Refer to page 296.



2010 CONGRESS-AT-A-GLANCE

	07:50 - 17:30	Epilepsy Review Course for Neuroscience Residents - Jose Martin del Campo
	08:00 - 17:00	Neurosurgery Resident Review Course: Neurovascular Disease
	00.00 - 17.00	- J. Max Findlay, Shobhan Vachhrajani
	08:30 - 17:00	ALS - David Cameron
	07:45 - 17:00	
tuesday		Advances in the Neurobiology of Disease - Peter Smith, Zelma Kiss
	08:30 - 17:00	Child Neurology Day - Cecil Hahn, Michelle Demos
june 8	12:00 - 13:30	Co-developed Industry Symposium (Stroke)
	18:00 - 20:00	Epilepsy Video Session - Richard McLachlan
	18:00 - 20:00	SIGS (Movement Disorders - David Grimes, Alex Rajput, Headache - Werner Becker,
üure		Neuromuscular Diseases - Kristine Chapman)
jur	ne 812	
	06:30 - 08:00	Co-developed Symposium (Headache)
	08:00 - 10:00 ^{°°}	Grand Opening Plenary -Scientific & Technical Advances in the Clinical Neurosciences:
		Jim Rutka (Penfield Lecture), Anthony Lang (Richardson Lecture), Josep Dalmau (Tibbles Lecture)
the state of the state	10:00 - 10:15	Break
and the set of the	10:15 - 11:45	Chairs' Select Plenary Presentations
1	12:00 - 13:30	Co-developed Symposium (Epilepsy)
	12:00 - 13:30	Co-developed Symposium (Neuropathic Pain) Headache - Jonathan Gladstone
wednesday	13:30 - 17:00	Headache - Jonathan Gladstone
june 9	13:30 - 17:00	Stroke - Ariane Mackey
	13:30 - 17:00	Neurovascular Surgery - R. Loch MacDonald
	13:30 - 17:00	Epilepsy - S. Nizam Ahmed
- wedi	13:30 - 17:00	Neuro-oncology - David Eisenstat, Claude Shields
and the second	13:30 - 17:00	Multiple Scierosis - Francois Emond
	17:00 - 19:30	Exhibitors Reception
		30
and the second second	08:30 - 10:00	Plenary-CNS, CSCN, & CACN Neurology- Cam Tesky (Gloor Lecture), & John Stewart
-	08:30 - 10:00	Plenary-CNSS Neurosurgery - Stephan Mayer, Ziya Gokaslan
	10:00 -10:15	Break
	10:15 - 12:30	Platforms (7 simultaneous)
thursday	12:30 - 14:00	Lunch/Exhibit Viewing/Digital Mini-platforms
june 10	14:00 - 16:30	Platforms (7 simultaneous) Digital Poster and Exhibit Viewing
june to	16:30 - 18:30	Digital Poster and Exhibit Viewing
#Brown	10 150 av	15.12.30Painns (7 similareas)
Guinsa	08:00 - 08:15	Journal Editor's Report
jjuli	08:15 - 08:30	CBANHC Report
	08:30 - 09:30	Distinguished guest lecture - James Orbinski
	09:30 - 09:45	Currently Active Canadian Clinical Trials
	09:45 - 10:15 _e	Break/Exhibit viewing
	10:15 - 12:00	Grand Rounds
friday	12:00 - 13:30	Lunch / Exhibit viewing / Digital Mini-platforms
june 11	13:30 - 17:00 _c	Neuro-ophthalmology - William Fletcher
June II	13:30 - 17:00	Interventional Neuroradiology - Alain Weill
	13:30 - 17:00	What's New in Neurosurgery - Pascale Lavoie
\wedge $-s_{s}$	13:30 - 17:00	Neurocritical Care - Draga Jichici, Jeanne Teitelbaum
Juches City	13:30 - 17:00	Neuromuscular Diseases Annie Dionne, Chris White
and the second s	13:30 - 17:00	Spine - Eric Massicotte
	13:30 - 17:00	What's New in Neurology - Nicolas Dupre
lle de Québic	13:30 - 17:00	EEG - Seved Mirsattari
Ala I	19	DRI CANADA
Quicibre Citt		

A-3

https://doi.org/10.1017/S0317167100118049 Published online by Cambridge University Press



Volume 37 / Number 2 / Ma

March 2010

Editor-in-Chief/Rédacteur en chef G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB Michael Shevell MONTREAL, QC Timothy J. Benstead HALIFAX, NS Mike Poulter LONDON, ON Serge Gauthier VERDUN, QC

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB James A. Sharpe TORONTO, ON Robert G. Lee CALGARY, AB Robert T. Ross WINNIPEG, MB (Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'éditorial

Jorge Burneo LONDON, ON Richard Desbiens QUEBEC CITY, QC David Fortin SHERBROOKE, QC Mark Hamilton CALGARY, AB Robert Hammond LONDON, ON Hans-Peter Hartung DUSSELDORF, GERMANY Michael Hill CALGARY, AB Alan C. Jackson WINNIPEG, MB Daniel Keene OTTAWA, ON Terence Myles CALGARY, AB James Perry TORONTO, ON Oksana Suchowersky CALGARY, AB Brian Toyota VANCOUVER, BC Brian Weinshenker ROCHESTER, MN, USA Samuel Wiebe CALGARY, AB Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie Richard Farb TORONTO, ON David Pelz LONDON, ON

Neuropathological Conference/Conférence sur la neuropathologie Robert Hammond LONDON, ON

Book Review/Critiques de livres Andrew Kirk SASKATOON, SK

Critically Appraised Topic Summaries (CATS)

Jorge Burneo LONDON, ON Mary Jenkins LONDON, ON

e-CPD (Web) Editor Mandar Jog LONDON, ON

Editorial Review Board/Conseil de Revue d'éditorial

Donald Brunet KINGSTON, ON Lionel Carmant MONTREAL, QC Colin Chalk MONTREAL, QC K. Ming Chan EDMONTON, AB Robert Chen TORONTO, ON Mary Connolly VANCOUVER, BC Joseph Dooley HALIFAX, NS Daryl Fourney SASKATOON, SK Hannah Glass SAN FRANCISCO, CA, USA Alan Goodridge ST. JOHN'S, NL Ian Grant HALIFAX, NS Alan Guberman OTTAWA, ON John Hurlbert CALGARY, AB Manouchehr Javidan VANCOUVER, BC Patrick McDonald WINNIPEG, MB Martin McKeown VANCOUVER, BC Joseph Megyesi LONDON, ON Vivek Mehta EDMONTON, AB Steven Miller VANCOUVER, BC Neelan Pillay CALGARY, AB Christopher Power EDMONTON, AB Alex Rajput SASKATOON, SK Jean Raymond MONTREAL, QC Gary Redekop VANCOUVER, BC Mark Sadler HALIFAX, NS Harvey Sarnat CALGARY, AB John Stewart VANCOUVER, BC Jeanne Teitelbaum MONTREAL, QC Eve Tsai OTTAWA, ON Shannon Venance LONDON, ON Matt Wheatley EDMONTON, AB Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, Chief Executive Officer Maggie McCallion, Designer/ Production Coordinator Cindy Leschyshyn, Editorial Coordinator

Advertising representative/Représentant de publicité:

Brett Windle Corporate Development Coordinator Tel (403) 229-9575 Fax (403) 229-1661 E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE Calgary, Alberta T2G 4B9 The official journal of: / La Revue officielle de:

The Canadian Neurological Society

La Société Canadienne de Neurologie The Canadian Neurosurgical Society La Société Canadienne de Neurochirurgie

The Canadian Society of Clinical Neurophysiologists La Société Canadienne de Neurophysiologie Clinique

The Canadian Association of Child Neurology L'Association Canadienne de Neurologie Pédiatrique

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at: Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situe en permanence à:

> 7015 Macleod Trail SW, Suite 709 Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bimonthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org COPYRIGHT© 2010 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences Postage paid at Calgary, Alberta. This journal is indexed by AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb SCL SCOPUS Swets TDB TOCprem

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel for pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web:www.cjns.org. DROITS D'AUTEUR© 2010: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'authorisation du Journal Canadien des Sciences Neurologiques. Port payé à Calgary, Alberta. Le Journal est cité et indexé dans AbHyg, AgBio, BIOBASE, BiolAb, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, EBSCO, Elsevier, EMBASE, ExcerpMed, HelmAb, Inpharma, JW-N, LTB, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, PN&I, ProtozoAb, PsycInfo, Reac, RefZh, RM&VM, RurDevAb, SCI, SCOPUS, Swets, TDB, TOCprem.

ISSN 0317 - 1671



Pr**MAXALT RPD**® (rizatriptan benzoate):


The Most Dispensed **Non-tablet Formulation Migraine Drug** in Canada¹

MAXALT RPD® 10 mg

ALSO AVAILABLE IN

Fast dissolving RPD wafer can be taken anytime, anywhere^{2,*}

ALSO AVAILABLE IN TABLET FORMULATION.



MAXALT® is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases should not receive MAXALT®.

MAXALT® is also contraindicated in patients with uncontrolled or severe hypertension.

MAXALT® is contraindicated in co-administration with monoamine oxidase (MAO) inhibitors within 2 weeks after discontinuation of treatment, and within 24 hours of administration of 5-HT1 agonists or ergot-type medications. For a complete list of contraindications, please consult the Product Monograph.

The recommended single adult dose is 5 mg. The maximum recommended single dose is 10 mg.

The most common adverse events during treatment with MAXALT® (rizatriptan benzoate) tablets 10 mg were dizziness (8.9%), somnolence (8.4%), asthenia/fatigue (6.9%), nausea (5.7%) and

Please visit our website at: www.merckfrosst.com



pain/pressure sensation (chest, 3.1%; neck/throat/jaw, 2.5%; upper limb, 1.8%).

The most common adverse events during treatment with PrMAXALT RPD® (rizatriptan benzoate) wafers 10 mg were dizziness (8.6%), nausea (7.0%), dry mouth (6.0%), somnolence (5.3%), asthenia/fatigue (3.6%), and pain/pressure sensation (chest, 1.7%; neck/throat/jaw, 2.0%; upper limb, 2.0%).

MAXALT RPD® wafers contain phenylalanine (a component of aspartame).

*The wafer will dissolve rapidly and be swallowed with saliva. No liquid is needed to take the wafer.²

RPD = Rapidly dissolving

References:

PAAB

MXT-08-CDN-34381016-JA A-5

- 1. Brogan Inc. Geographic Prescription Monitor (GPM®) September 2008 to August 2009.
- 2. Data on file, Merck Frosst Canada Ltd.: Product Monograph, MAXALT®, 2009.


BEFORE PRESCRIBING MAXALT®, PLEASE CONSULT THE ENCLOSED PRESCRIBING INFORMATION.

PRODUCT MONOGRAPH AVAILABLE FOR DOWNLOAD AT www.merckfrosst.com

®Registered Trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Used under license.



See prescribing summary on page A-14 to A-17



Bring your camera!!!

Québec City is truly one of the most beautiful cities in Canada.

Visitors can explore the historic downtown core as it was an original walled city with the Chateaux Frontenac overlooking the St. Lawrence seaway.

Rich in French culture and history, Québec City is known for its antique shops where treasures can be found around every corner.

As the capital of Québec, Québec City is a "must see" for any traveler to Canada.

Bienvenue à Québec!!

Join us for the Canadian Neurological Sciences Federation's

45th Annual Congress

June 8-11, 2010



<image>





Photos Courtesy of Ministère du Tourisme du Québec / FROM TOP TO BOTTOM / 1. Mondoux, Louise / 2. Hurteau, Paul; Parent, Claire / 3. Bourdeau, Jacques / 4. Bélanger, Christian

https://doi.org/10.1017/S0317167100118049 Published online by Cambridge University Press



A complete financial diagnosis includes helpful advice and practical solutions.

At Scotiabank, we have experts that can help you grow your business. Our *Scotia Professional®* Plan is a customized financial package that includes everything you need to set up and run a successful practice. You'll get competitive financing rates, flexible payback plans, and a dedicated advisor – all in one convenient package to meet your day to day banking, financing, and investment needs. It makes managing your money easy, so you can focus on serving your patients and growing your practice.

Learn more at any Scotiabank branch or visit www.scotiabank.com/professional

Scotia Professional Plan



You're richer than you think:

® Registered trademarks of The Bank of Nova Scotia.

https://doi.org/10.1017/S0317167100118049 Published online by Cambridge University Press

A-7



Fibromyalgia pain is real. And so is treatment with LYRICA.



LYRICA is the first treatment indicated in Canada for the management of pain associated with fibromyalgia in adults

- LYRICA is proven to manage the pain associated with fibromyalgia1
- LYRICA has been demonstrated to significantly improve pain-related sleep difficulties²
 - LYRICA reduced overall MOS-Sleep Scale scores significantly more from baseline versus placebo [LYRICA 300 mg/day -19.1 (p=0.0174), LYRICA 450 mg/day -20.41 (p=0.0026), and LYRICA 600 mg/day -19.49 (p=0.0101) vs -14.29 for placebo]^{2*}

The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

The most commonly observed dose-related adverse events in LYRICA-treated patients were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly reported (2.5% and twice the rate of that seen in placebo) treatment-related adverse events were: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). Adverse events for LYRICA and placebo, respectively, were 20% and 11%. There was a

dose-dependent increase in rate of discontinuation due to adverse events.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

See Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

References: 1. LYRICA Product Monograph. Pfizer Canada Inc., March 2009. 2. Mease PJ et al. A randomized, doubleblind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14.

* A multicenter, double-blind, 13-week, randomized trial. 748 patients who met the ACR criteria for fibromyalgia and who had an average mean pain score of ±4 on an 11-point numeric rating scale (NRS) during the baseline assessment were randomized to LYRICA 300 mg/day (n=185), 450 mg/day (n=183), 600 mg/day (n=190), or placebo (n=190). Patients were allowed to take acetaminophen up to 4 g/day as needed for pain relief. The number of completers was: LYRICA 300 mg/day (n=123), 450 mg/day (n=121), 600 mg/day (n=111), or placebo (n=130). The primary endpoint was the reduction in endpoint mean pain scores (mean of the last 7 daily pain scores while on study medication). Pain-related sleep difficulties were assessed using the Medical Outcomes Study-Sleep Scale (MOS-SS), a scale that runs from 0-100. Mean baseline MOS-SS score for overall sleep problem index was 65.0.



Working together for a healthier world™

© 2009 Pfizer Canada Inc. Kirkland, Quebec H9J 2M5

Inc. [™] Pfizer Inc, used under license LYRICA® C.P. Pharmaceuticals International C.V., owner/Pfizer Canada Inc., Licensee





A-8